All Relations between Alzheimer Disease and cholinergic receptor, nicotinic

Publication Sentence Publish Date Extraction Date Species
Justin W Kenney, Thomas J Goul. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Molecular neurobiology. vol 38. issue 1. 2008-10-15. PMID:18690555. drugs that act at nachrs can have cognitive-enhancing effects and diseases that disrupt cognition such as alzheimer's disease and schizophrenia are associated with altered nachr function. 2008-10-15 2023-08-12 Not clear
Min Hu, Jeffrey F Waring, Murali Gopalakrishnan, Jinhe L. Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells. Journal of neurochemistry. vol 106. issue 3. 2008-09-15. PMID:18485099. this study provides evidence of nachr mechanisms underlying abeta(1-42) toxicity and tau phosphorylation, which, if translated in vivo, could provide additional basis for the utility of alpha7 nachr ligands in the treatment of alzheimer's disease. 2008-09-15 2023-08-12 mouse
A Marighetto, S Valerio, A Desmedt, J N Philippin, C Trocmé-Thibierge, P Morai. Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Psychopharmacology. vol 197. issue 3. 2008-08-29. PMID:18265960. the comparative effects of a newly described specific alpha7 nachr partial agonist, s 24795, and a cholinesterase inhibitor, donepezil, currently used as a symptomatic alzheimer's disease treatment were studied in two mouse models of aging-related memory deficits. 2008-08-29 2023-08-12 mouse
C A Briggs, M R Schrimpf, D J Anderson, E J Gubbins, J H Grønlien, M Håkerud, H Ween, K Thorin-Hagene, J Malysz, J Li, W H Bunnelle, M Gopalakrishnan, M D Meye. alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues. British journal of pharmacology. vol 153. issue 5. 2008-05-15. PMID:18157163. the alpha7 nicotinic acetylcholine receptor (nachr) has attracted considerable interest as a target for cognitive enhancement in schizophrenia and alzheimer's disease. 2008-05-15 2023-08-12 Not clear
C Chipana, J Camarasa, D Pubill, E Escubed. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology. vol 29. issue 1. 2008-05-02. PMID:17980434. the aim of the present study was to investigate the utility of memantine (mem), an alpha-7 nachr antagonist used for treatment of alzheimer's disease patients, to prevent neurotoxicity induced by mdma in rats and the oxidative effect of this amphetamine derivative in mice striatal synaptosomes. 2008-05-02 2023-08-12 mouse
Ramin Faghih, Gregory A Gfesser, Murali Gopalakrishna. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Recent patents on CNS drug discovery. vol 2. issue 2. 2008-02-15. PMID:18221220. the alpha7 subtype of the nicotinic acetylcholine receptor (nachr) is a target of considerable interest in cns drug discovery, in part due to its implication in diseases of unmet medical need such as schizophrenia and alzheimer's disease. 2008-02-15 2023-08-12 cattle
Xiao-Lan Qi, Agneta Nordberg, Jin Xiu, Zhi-Zhong Gua. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochemistry international. vol 51. issue 6-7. 2007-12-21. PMID:17493709. in order to examine the neuroprotective effects of the alpha7 nicotinic receptor (nachr) in relationship to the pathogenesis of alzheimer's disease (ad), neuroblastoma (sh-sy5y) cells were transfected with small interference rnas (sirnas) that targets specifically towards alpha7 nachr or exposed to 20microm 3-[2,4-dimethoxybenzylidene] anabaseine (dmxb), a selective agonist of this same receptor. 2007-12-21 2023-08-12 Not clear
Robert S Bitner, William H Bunnelle, David J Anderson, Clark A Briggs, Jerry Buccafusco, Peter Curzon, Michael W Decker, Jennifer M Frost, Jens Halvard Gronlien, Earl Gubbins, Jinhe Li, John Malysz, Stella Markosyan, Kennan Marsh, Michael D Meyer, Arthur L Nikkel, Richard J Radek, Holly M Robb, Daniel Timmermann, James P Sullivan, Murali Gopalakrishna. Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 39. 2007-11-07. PMID:17898229. our results demonstrate that alpha7 nachr agonism can lead to broad-spectrum efficacy in animal models at doses that enhance erk1/2 and creb phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as alzheimer's disease and schizophrenia. 2007-11-07 2023-08-12 mouse
Stephen P Arneric, Mark Holladay, Michael William. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17662959. the current overview outlines the chronology of drug discovery efforts in nachrs from the cloning of the receptor family in the 1980s, to initial research efforts at sibia, r.j. reynolds and abbott, to the current industry-wide interest in nachr agonists as novel therapeutics for pain, schizophrenia and alzheimer's disease. 2007-11-06 2023-08-12 Not clear
Henrik H Hansen, Daniel B Timmermann, Dan Peters, Carrie Walters, M Imad Damaj, Jens D Mikkelse. Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. Journal of neuroscience research. vol 85. issue 8. 2007-11-05. PMID:17455307. it is considered that activation of nicotinic alpha7 receptors (alpha7 nachr) is useful for the treatment of cognitive disturbances in schizophrenia and alzheimer's disease. 2007-11-05 2023-08-12 mouse
Cristiane Lopes, Edna F R Pereira, Hui-Qiu Wu, Puranik Purushottamachar, Vincent Njar, Robert Schwarcz, Edson X Albuquerqu. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. The Journal of pharmacology and experimental therapeutics. vol 322. issue 1. 2007-08-30. PMID:17446300. galantamine, a drug used to treat alzheimer's disease, is a nicotinic allosteric potentiating ligand, and kynurenic acid (kyna), a neuroactive metabolite of the kynurenine pathway, is an endogenous noncompetitive inhibitor of alpha7* nicotinic receptors (nachrs) [the asterisk next to the nachr subunit is intended to indicate that the exact subunit composition of the receptor is not known (pharmacol rev 51:397-401, 1999)]. 2007-08-30 2023-08-12 rat
Dayong Wang, Yukihiro Noda, Yuan Zhou, Akihiro Mouri, Hiroyuki Mizoguchi, Atsumi Nitta, Weiduo Chen, Toshitaka Nabeshim. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 6. 2007-07-27. PMID:17133263. in the present study, we investigated whether galantamine exerts cognitive improving effects through the allosteric modulation of nachr in the intracerebroventricular beta amyloid (abeta)(25-35)-injected animal model of alzheimer's disease. 2007-07-27 2023-08-12 mouse
Ian W Jones, Adam Westmacott, Elcie Chan, Roy W Jones, Kelly Dineley, Michael J O'Neill, Susan Wonnacot. Alpha7 nicotinic acetylcholine receptor expression in Alzheimer's disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes. Journal of molecular neuroscience : MN. vol 30. issue 1-2. 2007-02-23. PMID:17192639. western blot and autoradiographic analyses indicate that the alpha7 nachr subunit protein is up-regulated in human brain samples from alzheimer patients, as well as in animal models of ad (dineley et al., 2001; bednar et al., 2002), and might be involved in nicotine-mediated reduction of abeta1-42 deposition (hellstrom et al., 2004), although the nature of this relationship remains ill-defined. 2007-02-23 2023-08-12 mouse
Jörn Schmaljohann, Daniela Gündisch, Martina Minnerop, Jan Bucerius, Alexius Joe, Michael Reinhardt, Stefan Guhlke, Hans-Jürgen Biersack, Ullrich Wüllne. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nuclear medicine and biology. vol 33. issue 3. 2006-12-18. PMID:16631078. nicotinic acetylcholine receptors (nachr) are involved in many physiological functions and appear to be affected in neurodegenerative diseases like alzheimer's disease and parkinson's disease (pd). 2006-12-18 2023-08-12 human
Mikako Ogawa, Ryo Tatsumi, Masakazu Fujio, Jiro Katayama, Yasuhiro Magat. Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor alpha7 subtype imaging agent. Nuclear medicine and biology. vol 33. issue 3. 2006-12-18. PMID:16631079. some in vitro investigations have suggested that the nicotinic acetylcholine receptor (nachr) alpha7 subtype is implicated in alzheimer's disease, schizophrenia and others. 2006-12-18 2023-08-12 Not clear
Anatoly Mazurov, Terry Hauser, Craig H Mille. Selective alpha7 nicotinic acetylcholine receptor ligands. Current medicinal chemistry. vol 13. issue 13. 2006-08-03. PMID:16787204. selective alpha7 nachr agonists have been developed as potential candidates for the treatment of schizophrenia, cognitive disorders (including alzheimer's disease), and inflammation. 2006-08-03 2023-08-12 Not clear
Elaine A Gay, Rebecca C Klein, Jerrel L Yake. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. The Journal of pharmacology and experimental therapeutics. vol 316. issue 2. 2006-04-04. PMID:16249370. for decades, the pathology of alzheimer's disease has been associated with dysfunction of cholinergic signaling; however, the cellular mechanisms by which nicotinic acetylcholine receptor (nachr) function is impaired in alzheimer's disease are as yet unknown. 2006-04-04 2023-08-12 rat
Raymond S Hurst, Mihaly Hajós, Mario Raggenbass, Theron M Wall, Nicole R Higdon, Judy A Lawson, Karen L Rutherford-Root, Mitchell B Berkenpas, W E Hoffmann, David W Piotrowski, Vincent E Groppi, Geraldine Allaman, Roch Ogier, Sonia Bertrand, Daniel Bertrand, Stephen P Arneri. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 17. 2006-03-09. PMID:15858066. several lines of evidence suggest a link between the alpha7 neuronal nicotinic acetylcholine receptor (nachr) and brain disorders including schizophrenia, alzheimer's disease, and traumatic brain injury. 2006-03-09 2023-08-12 human
Andon N Placzek, Francesca Grassi, Edwin M Meyer, Roger L Papk. An alpha7 nicotinic acetylcholine receptor gain-of-function mutant that retains pharmacological fidelity. Molecular pharmacology. vol 68. issue 6. 2006-01-19. PMID:16186249. the alpha7-type nicotinic acetylcholine receptor (nachr) has been recognized as a potential therapeutic target for the treatment of a variety of pathologic conditions, including schizophrenia, alzheimer's disease, and peripheral inflammation. 2006-01-19 2023-08-12 xenopus_laevis
Jacques Barik, Federico Dajas-Bailador, Susan Wonnacot. Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells. British journal of pharmacology. vol 145. issue 8. 2005-12-02. PMID:15937519. in this study, we have examined cellular responses of neuroblastoma sh-sy5y cells after chronic treatment with galantamine, a drug used to treat alzheimer's disease that has a dual mechanism of action: inhibition of acetylcholinesterase and allosteric potentiation of nicotinic acetylcholine receptors (nachr). 2005-12-02 2023-08-12 human